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Abstract: Influenza is a significant public health problem and the elderly are at a greater risk of
contracting the disease. The vaccination coverage of the elderly is below the Spanish target of 65% for
each influenza season. The aims of this study were to report the coverage of influenza vaccination
in Spain among the population aged ≥65 years and high-risk groups for suffering chronic diseases,
to analyze the time trends from 2006 to 2017 and to identify the factors which affect vaccination
coverage. A nationwide cross-sectional study was conducted including 20,753 non-institutionalized
individuals aged ≥65 years who had participated in the Spanish National Health Surveys in 2006,
2011/2012, and 2017. Sociodemographic, health-related variables, and influenza vaccination data
were used. A logistic regression analysis was performed to determine the variables associated with
influenza vaccination. Influenza vaccination coverage was 60%. By chronic condition, older people
with high cholesterol levels and cancer had the lowest vaccination coverage (62.41% and 60.73%,
respectively). This coverage declined from 2006 to 2017 in both groups. Higher influenza vaccination
was associated with males, Spanish nationality, normal social support perceived, polypharmacy,
worse perceived health, participation in other preventive measures, and increasing age and the
number of chronic diseases.
Keywords: aged; influenza; human; influenza vaccines; vaccination coverage; trends
1. Introduction
Influenza is a significant public health problem which causes high mortality and morbidity
rates [1]. Globally, seasonal influenza epidemics are estimated to lead to between 3 and 5 million cases
of severe illness, while up to 650,000 persons die as a result [2], with most related deaths occurring
among the elderly population and those with underlying chronic diseases [3]. Influenza also generates
high social and health care costs [4,5].
Nowadays, the annual influenza vaccine is considered the main and most effective strategy to
reduce the mortality and morbidity resulting from influenza, and its associated complications in
high-risk individuals [6–9]. In Europe, the seasonal influenza vaccine is recommended for the elderly
population and those at increased risk of influenza complications and severe disease, as well as for
patients with chronic conditions [10]. Even though vaccination against influenza is free in Spain in all
these cases, and that patients are normally vaccinated in primary care health centers [11], the vaccination
coverage reported from representative national surveys is below 60% in older people and continues
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to be lower than the desired rate [12,13]. Here, the World Health Organization (WHO) recommends
a minimum 75% vaccination coverage for the elderly population; however, in Spain, the objective
is to reach 65% coverage in this group and to move closer to the goal established by the WHO [14].
The impact of not reaching an optimal vaccination uptake on public health is relevant, since a 1%
decrease in associate mortality has been estimated to result from a 2.2% absolute increase in vaccination
coverage [15].
In the European countries in 2017, 44.3% of people aged 65 and over were vaccinated against
influenza [16] and 67.5% in the United States in 2016 [17]. Nowadays, people aged ≥65 years currently
constitute 19.40% of the Spanish population [18]. In addition, the Spanish National Statistics Office
predicts that this proportion will increase to 25.20% by 2033 [19]. Due to these situations as well as
the lack of favorable evolution of the vaccination coverage, there is a clear need to study the factors
related to regular vaccination. In that sense, prompt and efficient strategies to overcome barriers to
vaccination could be devised. The main objectives of the present study were to report the coverage of
influenza vaccination in Spain among the population aged ≥65 years and high-risk groups for suffering
chronic medical conditions, to analyze time trends from 2006 to 2017, and to identify vaccination
uptake factors.
2. Materials and Methods
2.1. Design and Study Population
A nationwide cross-sectional descriptive study was carried out from February to April 2020 using
the data obtained from the records of the Spanish National Health Survey (SNHS) 2006 (from June 2006
to June 2007) [20], 2011/2012 (from July 2011 to June 2012) [21], and 2017 (from October 2016 to
October 2017) [22]. The SNHS is a representative survey of the general population carried out by the
Ministry of Health, Consumer Affairs and Social Welfare in partnership with the National Institute of
Statistics, whose representativeness is ensured by assigning a weighting coefficient to each participant.
This survey is conducted in non-institutionalized Spanish residents through personalized interviews.
The sampling design was multistage probabilistic, stratified by census areas (first stage), family homes
(second stage), and individuals (third stage). The present study included people aged ≥65 years old
resident in Spain. Adults with dual nationality were excluded from the study. The initial sample
consisted of 20,753 subjects (7835 in 2006; 5896 in 2011/2012; and 7022 in 2017), but, due to a lack of
data for some of the variables studied, 5446 (26.24%) were excluded when the multivariate statistical
analyses were carried out. The excluded subjects did not differ systematically from the rest of sample.
2.2. Variables
The dependent variable was “influenza vaccination”. This variable was assessed through the
question: “Were you vaccinated against influenza during the last vaccination campaign?” Participants
who answered “yes” were considered as having been vaccinated.
The independent variables were as follows.
Sociodemographic variables were: Year of survey (2006, 2011/2012, 2017); gender (male,
female); age (65–74 years, 75–84 years, ≥85 years); nationality (Spanish, foreigner); level of
education (without studies, primary, secondary or professional training, university); marital status
(single, married, widowed, separated/divorced); size of town of residence (<10,000 inhabitants,
10,000–100,000 inhabitants, >100,000 inhabitants); and social class, which was assigned according
to the categories proposed by the Spanish Society of Epidemiology [23] and classified as Class I
(directors and managers of companies with 10 or more employees and professionals normally qualified
with university degrees), Class II (directors and managers of companies with fewer than 10 salaried
employees, professionals normally qualified with university degrees and other technical support
professionals, athletes, and artists), Class III (intermediate professions and self-employed workers),
Class IV (supervisors and workers in skilled technical work), Class V (skilled workers in the primary
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sector and other semi-skilled workers), and Class VI (unskilled workers). In this study, these six
original classes were reduced to three groups from lowest to highest socioeconomic status (Classes I
and II, Classes III and IV, and Classes V and VI).
Health-related variables were: Self-perceived health (very good, good, fair, poor, very poor);
blood cholesterol level measurement in the last year (yes, no); blood pressure taken by a healthcare
professional in the last year (yes, no); degree of limitation due to a health problem for at least six months
(severely limited, limited but not severely, not at all limited); and body mass index (BMI), which was
calculated from the self-reported body weight and height and categorized according to the World
Health Organization [24] as underweight (BMI <18.50 kg/m2), normal-weight (BMI 18.50–24.99 kg/m2),
overweight (BMI 25.00–29.99 kg/m2), and obese (BMI ≥30 kg/m2). To identify those chronic conditions
for which annual influenza vaccination was recommended in Spain, the participants were classified as
having the disease if they answered affirmatively to the question “Have you ever been diagnosed by a
physician with any of the following diseases?” after showing them a list including diabetes, cancer,
asthma, chronic bronchitis/emphysema/chronic obstructive pulmonary disease, arterial hypertension,
myocardial infarction, cholesterol, and ictus; presence of chronic conditions (none, 1–2, ≥3); and
polypharmacy, which was calculated using an identical question in all the questionnaires “From the
following list of types of medication, which have you consumed in the last two weeks?”. Subjects
were classified as polypharmacy if they gave an affirmative answer to the question for ≥5 different
medication groups (including those used to treat diseases such as colds, flu, throat or lung infections,
symptoms such as pain or fever, or laxatives). Although no consensus has yet been reached on the
definition of polypharmacy, the threshold of ≥5 different medications was chosen because it has
been used in recent studies conducted in different countries [25–27] and it is the most widely-used
formula [28].
To measure qualitative and functional aspects of social support, the Duke-UNC-11
questionnaire [29], adapted to the Spanish population [30,31], was used. This scale includes 11
items which are scored on a Likert-like scale ranging from 1 (“Much less than I would like”) to
5 (“As much as I would like”). The overall perceived social support is obtained by adding the scores of
the 11 items. The results range from 11 to 55 points. The final score is a dichotomized measure of the
perceived social support: optimal support (≥33 points) and sup-optimal support (≤32 points).
2.3. Procedure
The data obtained from these surveys are available in the National Institute of Statistics and
Ministry of Health, Consumer Affairs and Social Welfare websites [18–20] and were downloaded from
these sites. According to the SNHS methodology, the microdata files are anonymous and are available
to the public. In accordance with Spanish legislation, when secondary data are used, there is no need
for approval from an Ethics Committee. The data research is available in the Supplementary File S1.
2.4. Data Analysis
A descriptive analysis was performed by calculating the counts and percentages for the qualitative
variables and the quantitative variables by calculating the arithmetic mean and standard deviation (SD).
The proportions of categorical variables were compared using the chi-square test for contingency tables
or Fisher’s exact test if the number of expected frequencies was greater than 5. In addition, a logistic
regression was performed to identify the variables associated with influenza vaccination. In the
multivariate analysis, variables showing potential association with influenza vaccination (p ≤ 0.15) in
the univariate analysis were included, and backward selection was used to eliminate non-significant
variables based on the probability of the Wald statistic. Raw and adjusted odds ratios were calculated
with 95% confidence intervals. The goodness of fit was verified with the Hosmer–Lemeshow test.
All the hypothesis contrasts were bilateral and, in all the statistical tests, those with a 95% confidence
level (p < 0.05) were considered significant values. The statistical analysis was carried out using IBM
SPSS Statistics version 25 (IBM Corp, Armonk, NY, USA).
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3. Results
3.1. Sociodemographic and Health-Related Variables
The total sample was 20,753 records of people ≥65 years old. The subjects had the following
characteristics: predominantly female gender (62.01%; CI 95% 61.34–62.66%) and a mean age of
75.63 years (SD ± 7.22, CI 95% 75.53–75.72). Additionally, 38.11% had completed secondary or
professional training (CI 95% 37.45–38.77%), 49.94% were married (CI 95% 49.26–50.62%), 42.92%
belonged to social Classes V and VI (CI 95% 42.25–43.59%), 99.16% were Spanish (CI 95% 99.02–99.27%),
and 39.17% lived in towns with a population of over 100,000 inhabitants (CI 95% 38.51–39.84%).
In terms of body mass index, 37.30% were overweight (CI 95% 36.64–37.96%) (underweight
(BMI <18.50 kg/m2), normal-weight (BMI 18.50–24.99 kg/m2), overweight (BMI 25.00–29.99 kg/m2),
and obese (BMI ≥30 kg/m2)). On the other hand, 36.29% considered their health status good when
answering a subjective question on the topic (CI 95% 35.64–36.95%). A total of 71.87% had, at least,
three chronic conditions (CI 95% 71.25–72.48%), 75.81% had no polypharmacy (CI 95% 75.22–76.39%),
and 55.70% did not report any degree of limitation in the last six months (CI 95% 55.03–56.38%).
The social support was also assessed and 90.75% of participants perceived a normal level of social
support (CI 95% 90.35–91.14%). Regarding the participation in other control and prevention measures
against chronic conditions, the participation in influenza vaccination (60%; CI 95% 59.38–60.71%) was
inferior to that for blood pressure (98.22%; CI 95% 98.03–98.39%) and cholesterol (95.31%; CI 95%
95.02–95.59%) measurements.
According to the year of the survey (Table 1), an increase in the number of older people with
severe limitation due to a health problem (2006: 10.23%; 2011/2012: 9.75%; and 2017: 10.78%; p < 0.001)
and belonging to the social Classes V and VI (2006: 29.74%; 2011/2012: 52.53%; and 2017: 49.56%;
p < 0.001) can be seen.
Table 1. Sociodemographic and health-related characteristics of people aged ≥65 years in Spain.
Spanish National Health Surveys 2006–2017.
Variables
2006 2011/2012 2017 p-Value
n = 7835 (%) n = 5896 (%) n = 7022 (%)
Gender
<0.001Female 5022 (64.10) 3673 (62.30) 4173 (59.43)
Male 2813 (35.90) 2223 (37.70) 2849 (40.57)
Age group
<0.001
65–74 years 3931 (50.17) 2731 (46.32) 3382 (48.16)
75–84 years 3157 (40.30) 2350 (39.86) 2543 (36.22)
≥85 years 747 (9.53) 815 (13.82) 1097 (15.62)
Nationality
<0.001
Spanish 7736 (98.74) 5826 (98.81) 7016 (99.91)
Foreigner 71 (0.91) 69 (1.17) 2 (0.03)
Do not know/answer 28 (0.35) 1 (0.02) 4 (0.06)
Level of education
<0.001
University 522 (6.66) 325 (5.51) 634 (9.03)
Secondary or PT 4388 (56.00) 1882 (31.92) 1638 (23.33)
Primary 2428 (30.99) 1374 (23.30) 2614 (37.22)
Without studies 473 (6.04) 2315 (39.27) 2136 (30.42)
Do not know/answer 24 (0.31) 0 (0.00) 0 (0.00)
Marital status
<0.001
Single 773 (9.87) 489 (8.29) 572 (8.14)
Married 3886 (49.60) 2912 (49.39) 3566 (50.78)
Widowed 2991 (38.17) 2310 (39.18) 2567 (36.56)
Separated/Divorced 174 (2.22) 180 (3.05) 306 (4.36)
Do not know/answer 11 (0.14) 5 (0.09) 11 (0.16)
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Variables
2006 2011/2012 2017 p-Value
n = 7835 (%) n = 5896 (%) n = 7022 (%)
Social class
<0.001
Classes I and II 938 (11.97) 726 (12.31) 924 (13.16)
Classes III and IV 4247 (54.21) 1690 (28.66) 2284 (32.53)
Classes V and VI 2330 (29.74) 3097 (52.53) 3480 (49.56)
Do not know/answer 320 (4.08) 383 (6.50) 334 (4.75)
Size of town of residence
<0.001
>100,000 inhabitants 2810 (35.87) 2425 (41.13) 2894 (41.21)
10,000–100,000 inhabitants 2379 (30.36) 1743 (29.56) 2260 (32.19)
<10,000 inhabitants 2646 (33.77) 1728 (29.31) 1868 (26.60)
Body Mass Index
<0.001
Underweight 64 (0.82) 47 (0.80) 72 (1.02)
Normal weight 1738 (22.18) 1370 (23.23) 1978 (28.17)
Overweight 2784 (35.53) 2116 (35.89) 2840 (40.44)
Obese 1387 (17.70) 1158 (19.64) 1487 (21.18)
Do not know/answer 1862 (23.77) 1205 (20.44) 645 (9.19)
Self-perceived health
<0.001
Very good 430 (5.49) 359 (6.09) 441 (6.28)
Good 2581 (32.94) 2205 (37.40) 2745 (39.09)
Fair 3299 (42.11) 2175 (36.89) 2592 (36.92)
Poor 1177 (15.02) 915 (15.52) 977 (13.91)
Very poor 348 (4.44) 242 (4.10) 267 (3.80)
Presence of chronic conditions
<0.001
None 394 (5.03) 360 (6.11) 347 (4.94)
1–2 1842 (23.51) 1395 (23.66) 1500 (21.36)
≥3 5599 (71.46) 4141 (70.23) 5175 (73.70)
Blood cholesterol measurement
<0.001
No 379 (4.84) 317 (5.38) 49 (0.70)
Yes 7259 (92.65) 5555 (94.21) 6966 (99.20)
Do not know/answer 197 (2.51) 24 (0.41) 7 (0.10)
Blood pressure measurement
<0.001
No 89 (1.14) 123 (2.09) 38 (0.54)
Yes 7632 (97.41) 5770 (97.86) 6982 (99.43)
Do not know/answer 114 (1.45) 3 (0.05) 2 (0.03)
Degree of limitation due to a
health problem for at least 6
months
<0.001Not at all limited 4468 (57.03) 3562 (60.42) 3530 (50.27)
Limited but not severely 2565 (32.74) 1757 (29.80) 2734 (38.94)
Severely limited 802 (10.23) 575 (9.75) 757 (10.78)
Do not know/answer 0 (0.00) 2 (0.03) 1 (0.01)
Social support
<0.001
Low social support 347 (4.43) 251 (4.26) 400 (5.70)
Normal social support 7040 (89.85) 5206 (88.30) 6588 (93.82)
Do not know/answer 448 (5.72) 439 (7.44) 34 (0.48)
Polypharmacy
<0.001
Yes 1570 (20.04) 1426 (24.19) 1901 (27.07)
No 6208 (79.23) 4432 (75.17) 5093 (72.53)
Do not know/answer 57 (0.73) 38 (0.64) 28 (0.40)
PT, Professional Training; p-value is for trend.
3.2. Influenza Vaccination
The prevalence of influenza immunization decreased from 2006 to 2017 (2006: 66.08%; 2011/2012:
58.16%; and 2017: 54.91%; p < 0.001). As regards chronic conditions, we found the highest administration
of vaccine among those older people with bronchitis, emphysema, and/or chronic obstructive pulmonary
disease (71.40%), followed by asthma (70.52%), myocardial infarction (69.87%), and ictus (66.61%).
The lowest figures are shown in those with diabetes (65.69%), arterial hypertension (63.52%), high
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cholesterol (62.41%), and cancer (60.73%). There were significant differences in the numbers receiving
influenza vaccination in the different years of the study and the presence of chronic conditions. Over
the years, the participation in influenza vaccination campaigns which decreased most was among
older people with diabetes (2006: 71.89%; and 2017: 62.43%; p < 0.001), high cholesterol (2006: 68.38%;
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Figure 1. Patterns of influenza vaccination coverage according to chronic diseases in people aged
≥65 years in Spain. Spanish National Health Surveys 2006–2017.
3.3. Association between Sociodemographic and Health-Related Variables and Influenza Vaccination
The influenza vaccination is distributed differently according to sociodemographic and
health-related characteristics (Table 2). In the bivariate analysis, significant differences were observed
for all the sociodemographic and health status variables between those older people who had been
vaccinated against influenza and those who had not. In the multivariate analysis, the probability
of people aged ≥65 years old participating in the influenza vaccination campaign was higher in
males (of the total sample, 37.99% were males), in people who had participated in blood pressure
and cholesterol testing campaigns, those who perceived normal social support, and those with
polypharmacy, and was lower in foreign participants. Moreover, a clear upward trend was observed in
this probability with increased age and number of chronic diseases, and when the perceived health
was worse.
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Table 2. Association between participation in the influenza vaccination campaign, sociodemographic and health-related variables in people aged ≥65 years in Spain.
Spanish National Health Surveys 2006–2017.
Variables
2006 2011/2012 2017 Total
OR (CI 95%) p-Value ORa (CI 95%) p-Valuen = 5177 (%) n = 3429 (%) n = 3856 (%) n = 12,462 (%)
Gender
Female 3263 (63.03) 2122 (61.88) 2238 (58.04) 7623 (61.17) Reference Reference
Male 1914 (36.97) 1307 (38.12) 1618 (41.96) 4839 (38.83) 1.09 (1.03–1.16) <0.01 1.32 (1.23–1.41) <0.001
Age group
65–74 years 2312 (44.66) 1339 (39.05) 1520 (39.42) 5171 (41.49) Reference Reference
75–84 years 2307 (44.56) 1541 (44.94) 1614 (41.86) 5462 (43.83) 1.99 (1.87–2.11) <0.001 1.87 (1.74–2.02) <0.001
≥85 years 558 (10.78) 549 (16.01) 722 (18.72) 1829 (14.68) 2.08 (1.90–2.27) <0.001 2.08 (1.85–2.34) <0.001
Nationality
Spanish 5128 (99.05) 3399 (99.13) 3854 (99.95) 12,381 (99.35) Reference
Foreigner 30 (0.58) 30 (0.87) 0 (0.00) 60 (0.48) 0.42 (0.19–0.92) <0.01 Reference
Do not know/answer 19 (0.37) 0 (0.00) 2 (0.05) 21 (0.17) 0.86 (0.42–0.93) <0.01 0.61 (0.41–0.90) 0.01
Level of education
University 312 (6.03) 156 (4.55) 321 (8.33) 789 (6.33) Reference
Secondary or PT 2872 (55.48) 1056 (30.80) 800 (20.75) 4728 (37.94) 1.21 (1.14–1.48) <0.001
Primary 1645 (31.77) 831 (24.23) 1440 (37.34) 3916 (31.42) 1.11 (1.08–1.62) <0.001
Without studies 332 (6.41) 1386 (40.42) 1295 (33.58) 3013 (24.18) 1.13 (1.04–1.51) <0.001
Do not know/answer 16 (0.31) 0 (0.00) 0 (0.00) 16 (0.13) 1.27 (1.11–1.92) <0.001
Marital status
Single 462 (8.92) 290 (8.46) 309 (8.01) 1061 (8.51) Reference
Married 2609 (50.40) 1680 (48.99) 1972 (51.14) 6261 (50.24) 1.12 (0.99–1.23) 0.06
Widowed 2012 (38.86) 1385 (40.39) 1433 (37.17) 4830 (38.76) 1.16 (1.05–1.28) 0.01
Separated/Divorced 90 (1.74) 71 (2.07) 140 (3.63) 301 (2.42) 0.61 (0.51–0.73) <0.001
Do not know/answer 4 (0.08) 3 (0.09) 2 (0.05) 9 (0.07) 0.36 (0.16–0.82) 0.01
Social class
Classes I and II 617 (11.92) 379 (11.05) 470 (12.19) 1466 (11.76) Reference
Classes III and IV 2830 (54.67) 994 (28.99) 1231 (31.92) 5055 (40.56) 1.22 (1.12–1.33) <0.001
Classes V and VI 1532 (29.59) 1840 (53.66) 1970 (51.09) 5342 (42.87) 1.15 (1.05–1.25) 0.01
Do not know/answer 198 (3.82) 216 (6.30) 185 (4.80) 599 (4.81) 1.04 (0.91–1.21) 0.54
Size of town of residence
>100,000 inhabitants 1805 (34.87) 1379 (40.22) 1522 (39.47) 4706 (37.76) Reference
10,000–100,000 inhabitants 1530 (29.55) 992 (28.93) 1200 (31.12) 3722 (29.87) 1.02 (0.95–1.09) 0.6
<10,000 inhabitants 1842 (35.58) 1058 (30.85) 1134 (29.41) 4034 (32.37) 1.33 (1.24–1.42) <0.001
Body Mass Index
Underweight 41 (0.79) 25 (0.73) 34 (0.88) 100 (0.80) Reference
Normal weight 1111 (21.46) 767 (22.37) 1047 (27.15) 2925 (23.47) 0.82 (0.58–1.19) 0.16
Overweight 1819 (35.14) 1228 (35.81) 1580 (40.98) 4627 (37.13) 1.11 (1.07–1.21) 0.01
Obese 924 (17.85) 689 (20.09) 834 (21.63) 2447 (19.64) 1.13 (1.04–1.25) 0.01
Do not know/answer 1282 (24.76) 720 (21.00) 361 (9.36) 2363 (18.96) 1.28 (0.95- 1.73) 0.1
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Table 2. Cont.
Variables
2006 2011/2012 2017 Total
OR (CI 95%) p-Value ORa (CI 95%) p-Valuen = 5177 (%) n = 3429 (%) n = 3856 (%) n = 12,462 (%)
Self-perceived health
Very good 227 (4.38) 153 (4.46) 169 (4.38) 549 (4.41) Reference Reference
Good 1594 (30.79) 1170 (34.12) 1364 (35.37) 4128 (33.12) 1.51 (1.33–1.70) <0.001 1.31 (1.14–1.52) <0.001
Fair 2305 (44.52) 1371 (39.98) 1560 (40.46) 5236 (42.02) 2.30 (2.03–2.60) <0.001 1.56 (1.35–1.81) <0.001
Poor 812 (15.69) 591 (17.24) 585 (15.17) 1988 (15.95) 2.28 (1.99–2.61) <0.001 1.37 (1.16–1.62) <0.001
Very poor 239 (4.62) 144 (4.20) 178 (4.62) 561 (4.50) 2.35 (1.96–2.82) <0.001 1.43 (1.13–1.80) <0.01
Presence of chronic diseases
None 159 (3.07) 140 (4.08) 99 (2.57) 398 (3.19) Reference Reference
1–2 1058 (20.44) 672 (19.60) 661 (17.14) 2391 (19.19) 1.80 (1.57–2.06) <0.001 1.57 (1.33–1.84) <0.001
≥3 3960 (76.49) 2617 (76.32) 3096 (80.29) 9673 (77.62) 3.24 (2.87–3.70) <0.001 2.31 (1.97–2.71) <0.001
Blood cholesterol measurement
No 186 (3.59) 126 (3.67) 17 (0.44) 329 (2.64) Reference
Yes 4887 (94.40) 3291 (95.98) 3839 (99.56) 12,017 (96.43) 1.96 (1.69–2.27) <0.001 Reference
Do not know/answer 104 (2.01) 12 (0.35) 0 (0.00) 116 (0.93) 1.31 (0.97–1.76) 0.08 1.33 (1.10–1.61) <0.01
Blood pressure measurement
No 34 (0.66) 36 (1.05) 10 (0.26) 80 (0.64) Reference
Yes 5093 (98.38) 3392 (98.92) 3846 (99.74) 12,331 (98.95) 3.25 (2.49–4.25) <0.001 Reference
Do not know/answer 50 (0.96) 1 (0.03) 0 (0.00) 51 (0.41) 1.59 (1.02–2.50) 0.04 1.70 (1.20–2.40) <0.01
Degree of limitation due to a health
problem for at least 6 months
Not at all limited 2816 (54.40) 1945 (56.72) 1730 (44.87) 6491 (52.08) Reference
Limited but not severely 1778 (34.34) 1117 (32.58) 1642 (42.58) 4537 (36.41) 1.49 (1.32–1.78) <0.001
Severely limited 583 (11.26) 366 (10.67) 484 (12.55) 1433 (11.50) 1.44 (1.27–1.62) <0.001
Do not know/answer 0 (0.00) 1 (0.03) 0 (0.00) 1 (0.01) 1.50 (0.37–1.21) 0.1
Social support
Low social support 212 (4.09) 125 (3.65) 204 (5.29) 541 (4.34) Reference
Normal social support 4670 (90.21) 3043 (88.74) 3635 (94.27) 11,348 (91.06) 1.28 (1.13–1.46) <0.001 Reference
Do not know/answer 295 (5.70) 261 (7.61) 17 (0.44) 573 (4.60) 1.39 (1.16–1.67) <0.001 1.41 (1.19–1.67) <0.001
Polypharmacy
No 3959 (76.47) 2440 (71.16) 2598 (67.38) 8997 (72.19) Reference
Yes 1181 (22.81) 963 (28.08) 1238 (32.10) 3382 (27.14) 1.67 (1.56–1.79) <0.001 Reference
Do not know/answer 37 (0.72) 26 (0.76) 20 (0.52) 83 (0.67) 1.55 (1.06–2.27) 0.02 1.32 (1.21–1.45) < 0.001
PT, Professional Training; OR, odds ratio; ORa, odds ratio adjusted for all sociodemographic and health-related variables; CI 95%, 95% Confidence Interval; n, number of people
participating in vaccination campaigns for influenza; Hosmer–Lemeshow test χ2 = 2.29, p = 0.94; Nagelkerke’s R2: 0.08; p-value < 0.001.
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4. Discussion
The National Health Survey is an important tool that has been used in previous studies because
of its statistical potential as a representative national survey with a considerable sample size. However,
in the present study, foreign participants seem to be underrepresented. Both international [32] and
national [33] studies show that the foreign population has a lower participation in population social
and health surveys. Most of the identified barriers to participation in the health survey do not appear
to be related to ethnic background alone but reflect general issues pertaining to questionnaires of this
length and complexity. In addition, level of education and language barriers may be factors especially
influencing response rate [34].
The results of the present study provide an update on the mean influenza vaccination coverage
rate in older people in Spain, which is currently 60%. Although vaccination has been recommended for
many years, a huge disparity exists between the vaccination coverage of different countries (Table 3).
Table 3. Vaccination coverage of different countries.




















Denmark [36] 2009/2010 48.50%
United Kingdom [36] 2011/2012 74%
The different vaccination rates between those countries might be explained by the different
publicity campaigns supporting the vaccination recommendations, differences in the vaccination
systems and funding schemes, and different attitudes related to seasonal influenza vaccination.
Although there has been widespread consensus for many years that older age groups should be
vaccinated, and the WHO urges Member States of the Europe Union to carry out interventions and
strategies to facilitate increased influenza vaccination coverage for the elderly population, the United
Kingdom was the only country to come near to the Europe Union target of 75% in the 2015/2016 and
2016/2017 influenza seasons [38]. In the present study, the influenza vaccination coverage ranged
from 66.08% in 2006 to 54.94% in 2017. Despite the fact that, in some European countries (Germany,
Sweden, Portugal, Luxembourg, Poland, Slovenia, Denmark, Ireland, Italy, France, Netherlands,
Hungary, Romania, and Italy) an increasing trend was observed before 2009 pandemic [39], public
discussion about the effectiveness, safety, and necessity of influenza vaccination, especially during
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the 2009 pandemic, has created doubt among the general public about getting vaccinated against
influenza. This doubt may have contributed to the declining trend in influenza vaccination coverage
in most European countries over the last few years [40,41]. Other factors that may be considered in
decreasing coverage are conflicting messages about pandemic risk [42] and issues of complacency
(lower perceived severity of disease, lower perceived risk of disease) [43,44].
When analyzing predictors of influenza vaccination uptake (Table 2), males were associated with
higher rates of vaccination. Similar results have been reported in other studies from recent years [15]
and these could be explained by women reporting more adverse reactions to vaccines or there being a
lack of recommendations for them, as women are usually considered to be more aware of self-health
care and prevention compliance habits than men; another explanation could be a decreased perception
of vaccine safety and efficacy [45]. However, in other studies, either vaccination coverage was reported
to be higher among females [46–48] or no associations were found between those variables [49].
Three studies similar to ours performed in several countries found that older people (>70 years)
were associated with being more compliant regarding influenza vaccination [48,50,51]. Nevertheless,
Ganczak et al. [52] revealed that younger patients (<70 years) were almost eight times more likely to
receive the influenza vaccine, due to the fact that old age is often associated with imperfect functional
status, which may negatively influence the likelihood of vaccine uptake, since access might depend
on transportation or assistance. What these findings all show, however, is that further evidence is
needed. Martínez et al. [37] found that foreigners were less likely to uptake the vaccine than Spanish
people, in line with the results of the present study. Some prior studies have reported similar findings
regarding social and racial disparities on vaccination [53–55]. This may reflect the lesser degree of
primary medical care in the foreign population, who are subsequently less likely to have regular
vaccinations [43,56]. Spain provides access to healthcare to foreign people on the same basis as to
people with Spanish nationality in order that foreigners may not seek preventative healthcare services
due to lacking awareness of entitlements [57].
In the univariate analysis, older people with a lower educational level were more likely to
participate in influenza vaccination campaigns compared to those with university studies. This finding
is similar to that found in other studies [12,58]. Moreover, several studies conducted in European
countries where the vaccination of elderly persons is provided free-of-charge found that educational
level was not a major determinant of vaccination [49,59]. Regarding marital status, we found that being
widowed increased the decision to become immunized while being separated or divorced decreased
it. Despite some authors [60–62] finding no relationship between those variables, marital status is
considered an important predictor of healthcare utilization. In fact, marriage may influence health
status not only through the support and protection that marriage offers, but also through a more
efficient pattern of healthcare utilization. As for social class, there was a difference of the social class
distribution between 2006 and subsequent surveys. This may be due to the economic crisis that affected
Spain from 2008 to 2013. Between 2009 and 2013, the real gross domestic product fell by 5.2%, and the
unemployment rate increased from 8.6% in 2007 to 25.7% in 2013 [63]. Accordingly, the data for the
post-2008 period indicate a transformation of the social class in Spain with an increase in the number of
people belonging to the lower social class and a pronounced loss of weight for skilled manual workers
belonging to the middle social class. On the other side, there an increase of people who belonging
to upper social class, which may be explained by the well-proven fact that higher quality jobs (those
that require more human capital) offer better working conditions and more protection against the
job destruction associated with economic crisis [64]. In the univariate analysis, older people from
social Classes V and VI had a higher influenza vaccination coverage than those from higher classes.
This situation is similar to that found in some studies [12,65,66] and may be due to people from higher
social classes possibly being more susceptible to both anti-vaccination campaigns and the increased
perception of the potential risks of vaccinations [65].
Regarding the size of town, we found that the participation in influenza vaccination campaigns
by older people who lived in areas with <10,000 inhabitants was higher than others who lived in cities
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with >100,000 inhabitants. In rural settings, the healthcare professionals have closer relationships with
their patients, making it easier for them to promote local health services and personally recommend
campaigns of vaccinations; in addition, the information is more willingly accepted by patients [67].
In the current study, the univariate analysis showed that influenza coverage was higher in
overweight and obese older people than in those with a normal weight. According to a recent
systematic review and meta-analysis, people with obesity may be both more likely to perceive higher
risk from vaccine-preventable diseases and more accepting of the benefits and safety of recommended
vaccinations [68]. On the other hand, the results of this study are in line with other studies [51,69–71],
which show that poor self-perceived health status is associated with receiving vaccinations, while
a good self-perceived health status is the most common reason for the refusal to be vaccinated.
This finding can be explained because, among older people, the likelihood is that having a chronic
illness will influence their self-perceived health status. In addition, we observed that individuals
affected by one or more chronic diseases had a greater likelihood of being vaccinated against influenza
than those reporting non-chronic conditions. Previous studies conducted in Spain [53] and in other
countries [46,72–74] reported analogous findings. Despite the mistrust which older people with chronic
conditions have of vaccination and the fact that they often have a lower perceived risk of influenza
than of other without chronic diseases, being advised to take the influenza vaccination by their doctor
or nurse is a good way to promote vaccination uptake [46]. On the other hand, people without chronic
diseases feel that influenza is not a dangerous disease and more often than chronic patients choose not
to be vaccinated [46]. In addition, in the current study, patients with bronchitis, emphysema, and/or
chronic obstructive pulmonary disease and those with asthma showed the highest vaccination coverage.
This finding may be explained by the fact that respiratory diseases are closely related to influenza
complications, such a pneumonia, and vaccination is strongly recommended and effective to prevent
hospitalization among older people [75–78]. Regarding influenza vaccination as a recommended step
for cancer patients, cancer survivors, and those who are not currently undergoing treatment [79],
we observed that the lowest rate of influenza vaccination coverage was among the older people with
cancer. In line with our findings, vaccination rates found among these population in other studies
were also very low [74,78,80]. Another relevant result regarding individuals with chronic diseases
was that the biggest decrease in vaccination coverage from 2006 to 2017 was identified in older people
with diabetes, cholesterol, and myocardial infarction, which points to the need to conduct studies to
understand the barriers or aspects of patient behavior which account for this result (Figure 1).
In this study, an overwhelming majority (>95%) had had their blood pressure and cholesterol
measured in the last year and 59.15% had been given the influenza vaccination. In the multivariate
analysis, clinical preventive practices such as taking blood pressure and cholesterol values increased
the probability of participation in vaccination campaigns for influenza. In that sense, Spanish National
Health System advises that any contact with the health system should be used to establish the influenza
vaccination recommendation [81]. In another study using the same methodology [12], with an older
population, 90.90% and 86.20% of the participants affirmed that less than one year had elapsed
since they last had their blood pressure and blood cholesterol tested, respectively, and 63.36% had
received influenza immunization. It seems clear that the elderly population with chronic conditions
participate in other clinical preventive practices more than in influenza vaccination. This may occur
because, for example, patients who suffer from arterial hypertension go to see their nurse to control
their blood pressure while the reason for having an influenza vaccination is because older people
are a risk population, and they do not always they agree with this. Taking into account that the
cost-effectiveness results for influenza vaccination among adults is comparable to the cost-effectiveness
of other preventive health interventions targeting adults, including colorectal screening, breast cancer
screening, and arterial hypertension screening and treatment [82,83], healthcare professionals and
healthcare systems should invest their time and efforts into promoting, implementing and incentivizing
influenza vaccination programs to ensure all patients are given a strong recommendation for vaccination
and have the opportunity to benefit from it. Furthermore, most studies point out that people with
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greater limitations are less likely to receive the recommended care for their chronic conditions. In fact,
recommended care tends to decrease when the person’s limitations increase, and is substantially lower
among severely limited patients [84], which hinders their adherence to vaccination campaigns.
Consistent with previous studies [85,86], our results show that older people with a normal social
support were more likely to receive influenza vaccination than those with a lower social support.
Social support is considered a predictor of a healthy general lifestyle [85]. Interaction with others has
an impact on health-relevant behavior. They may support behavior change by offering instrumental
help or emotional encouragement [87,88]. Recommendations and communication from healthcare
personnel to improve the individual’s perceptions of their susceptibility to and the severity of a
health threat are the major influences on the likelihood of that person behaving in a way to avoid the
threat [89], which could facilitate vaccination uptake. This is an important issue to consider because
vaccination may reduce the problems related to polypharmacy in the elderly population with many
comorbidities, which may lead to major adverse effects or lack of compliance [90,91].
This study reflects the current state of influenza vaccination coverage in individuals aged 65
and older. It is vital therefore that our current knowledge about the factors that influence vaccine
coverage should be taken into consideration by health authorities when designing strategies to improve
influenza vaccination coverage. Even though there are several interventions which produce significant,
positive effects, such as sending postcards (low intensity), making personalized phone calls (medium
intensity), and making home visits (high intensity), all of which increase the community demand for
vaccination, enhance access and improve the provider/system [92], it is not enough simply to identify
the evidence about the benefits of a particular intervention. Those interventions require organized
procedures, and systematic, integrated processes must be followed to achieve both its initial adoption
and its medium- to long-term maintenance and convey to the elderly population the benefits provided
by a cost-effective intervention such as the influenza vaccine. In this way, it would be possible to
overcome the trend of decreasing influenza vaccination observed in Spain, which is falling to clearly
insufficient vaccination coverage rates.
The present study also has some limitations. Firstly, due to the cross-sectional design, it is not
possible to assign causality between vaccination and the related variables. It should be remembered
that the data collected in the surveys was obtained indirectly from the informants’ self-reporting,
which can be affected by memory and/or social desirability bias. Furthermore, the surveys also failed
to ask the people why they had or had not been vaccinated, which would be interesting to include in
future research. Moreover, the reliability of respondent’s answers about influenza vaccination cannot
be verified. In addition, foreign participants seem to be underrepresented, so results obtained from
these databases should be taken with caution. There are different strategies to increase the response
rate in the foreign population. In that sense, it would be desirable to translate the questionnaire into
various languages, to use surveyors belonging to the different communities, or to use specific types
of sampling, such as “snowball”. On the other hand, one strength of our study is that since the data
were derived from a national survey, they have been obtained using carefully planned methodology,
including sampling, well-designed forms, preparation of the survey participants, supervision of the
survey, and filtering of the data, all of which guarantee a representative sample of the population.
5. Conclusions
The coverage of influenza vaccination in the elderly population is 60%, which is clearly well
below the recommended level. Older people with bronchitis, emphysema, and/or chronic obstructive
pulmonary disease and those with asthma had the highest vaccination coverage and individuals with
high cholesterol and cancer the lowest. There is a decreased participation in the influenza vaccination
campaigns in older people, in general, and in elderly individuals with chronic conditions, in particular,
from 2006 to 2017. The likelihood of being vaccinated for influenza is higher in males; in individuals
who participate in other control and prevention measures against chronic conditions, such as blood
pressure and cholesterol measurement campaigns; in those with normal perceived social support; and
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in those with polypharmacy. In addition, the older is the patient, the more chronic conditions they
suffer from, and the worse their perceived health, the greater is the likelihood of them agreeing to be
vaccinated. By contrast, this likelihood is lower in foreigners.
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